Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells (Q34094070)

31 July 2017

title

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells (English)

1 reference

31 July 2017

2

Flavell RA

1 reference

31 July 2017

Gorelik L

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

7

1 reference

31 July 2017

issue

10

1 reference

31 July 2017

page(s)

1118-1122

1 reference

Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Regulation of immune responses by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Role of transforming growth factor beta in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Transforming growth factor beta secretion from primary breast cancer fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

RAG-1-deficient mice have no mature B and T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Introduction of soluble protein into the class I pathway of antigen processing and presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Prostate cancer in a transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

7 January 2021

Interleukin-2 suppresses activated macrophage intracellular killing activity by inducing macrophages to secrete TGF-beta.

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

7 January 2021

Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

7 January 2021

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNM1001-1118

7 January 2021

Identifiers

DOI

10.1038/NM1001-1118

1 reference

Dimensions Publication ID

31 July 2017

1011288043

0 references

1 reference